S. 2456Senate115th Congress (2017-2019)In Committee

CARA 2.0 Act of 2018

Introduced February 27, 2018

AI-Generated Summary

Updated April 15, 2026 at 8:38 PM UTC

The CARA 2.0 Act reauthorizes and expands the 2016 Comprehensive Addiction and Recovery Act. It adds new funding for education, first‑responder training, youth recovery programs, and treatment services, while tightening opioid prescribing rules and requiring broader use of prescription‑drug monitoring programs. The bill also broadens medication‑assisted treatment authority, sets standards for recovery housing, and increases penalties for opioid manufacturers.

Key Provisions

  • Adds $10 million per year (2019‑2023) for a national education campaign on addiction and recovery.
  • Creates a three‑day limit on initial opioid prescriptions for acute pain, requiring practitioners to certify they will not exceed that supply except for addiction‑treatment prescriptions.
  • Funds first‑responder training on fentanyl and other dangerous drugs and provides $300 million per year (2019‑2023) for that effort.
  • Increases funding for evidence‑based opioid‑treatment demonstrations by $300 million per year (2019‑2023) and expands eligibility to include Indian tribes.
  • Establishes regional technical assistance centers for recovery services and authorizes $200 million per year (2019‑2023) for them.
  • Lets states raise patient caps for medication‑assisted treatment, makes nurse‑practitioner‑type roles permanent, and expands the definition of qualifying practitioners.
  • Requires any federally funded program to offer at least one FDA‑approved opioid antagonist and one opioid agonist/partial agonist medication for treatment.
  • Creates a National Youth Recovery Initiative with $10 million per year (2019‑2023) for grants to schools, colleges, and nonprofits to provide recovery support services.
  • Directs HHS to publish best‑practice guidelines for recovery housing and to address licensing, zoning, and discrimination barriers.
  • Adds $100 million per year (2019‑2023) for treatment programs for pregnant and postpartum women, $20 million per year for veterans’ treatment courts, and $60 million per year for infant safe‑care plans.
  • Mandates that covered states require prescribers and dispensers to use prescription‑drug monitoring programs, with reporting and data‑sharing requirements; non‑compliance can lead to loss of federal grant funding.
  • Raises civil fines for opioid manufacturers to $100,000 for certain reporting violations and criminal fines to $500,000 for related offenses.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions
SenateCommittee Latest Action

Committee on the Judiciary Subcommittee on Crime and Terrorism. Hearings held.

April 11, 2018

View full timeline
SenateIntro Referral

Introduced in Senate

February 27, 2018

SenateIntro Referral

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

February 27, 2018

SenateCommittee

Committee on the Judiciary Subcommittee on Crime and Terrorism. Hearings held.

April 11, 2018

Floor Debate

5 members

What members said about S. 2456 on the floor

2 Republicans3 Democrats
Rob Portman
Sen. Rob PortmanR-OH · Feb 27, 2018

Mr. President, I want to address a critical issue today in Westerville, OH, and, frankly, every community I represent in my State and communities all over the country. Today, I want to talk about the…

Rob Portman
Sen. Rob PortmanR-OH · Feb 27, 2018

Mr. President, I want to address a critical issue today in Westerville, OH, and, frankly, every community I represent in my State and communities all over the country. Today, I want to talk about the…

Susan M. Collins
Sen. Susan M. CollinsR-ME · Feb 27, 2018

Mr. President, I rise to introduce the Terrorist Firearms Prevention Act, which would prohibit suspected or known terrorists from legally purchasing a firearm. I thank my colleagues--Senators…

Martin Heinrich
Sen. Martin HeinrichD-NM · Feb 27, 2018

Mr. President, I want to start by thanking my colleague, Senator Collins of Maine, for her work in crafting this legislation and the language of this bill and, more generally, for her leadership,…

Patrick J. Leahy
Sen. Patrick J. LeahyD-VT · Feb 27, 2018

Mr. President. No American should have to relinquish all of their privacy rights in their cell phones, laptops, and other electronic devices, simply because they are coming home from a trip abroad.…

Show 2 more
Rob Portman
Sen. Rob PortmanR-OH · Feb 27, 2018

Mr. President, I would like to talk today about two brave Ohioans who were tragically killed while serving their community and all of us. On Saturday, February 10, Ohio lost two of its finest when…

Tim Kaine
Sen. Tim KaineD-VA · Feb 27, 2018

Mr. President. We rightfully honor the sacrifice of veterans and servicemembers and as a member of the Senate Armed Services Committee, I am proud of the work we do to ensure that we have the best…

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in SenateIssued February 27, 2018

II

115th CONGRESS

2d Session

S. 2456

IN THE SENATE OF THE UNITED STATES

February 27, 2018

Mr. Portman (for himself, Mr. Whitehouse, Mrs. Capito, Ms. Klobuchar, Mr. Sullivan, Ms. Hassan, Mr. Cassidy, and Ms. Cantwell) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

A bill to reauthorize and expand the Comprehensive Addiction and Recovery Act of 2016.

1.

Short title

This Act may be cited as the CARA 2.0 Act of 2018.

2.

National Education Campaign

Section 102 of the Comprehensive Addiction and Recovery Act of 2016 (42 U.S.C. 290bb–25g) is amended by adding at the end the following:

(d)

Authorization of appropriations

There is authorized to be appropriated to carry out this section, $10,000,000 for each of fiscal years 2019 through 2023.

.

3.

Three-day limit on opioid prescriptions

Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended by adding at the end the following:

(l)

Three-Day limit on opioid prescriptions

(1)

Definitions

In this subsection—

(A)

the term acute pain

(i)

means pain with abrupt onset and caused by an injury or other process that is not ongoing; and

(ii)

does not include—

(I)

chronic pain;

(II)

pain being treated as part of cancer care;

(III)

hospice or other end-of-life care; or

(IV)

pain being treated as part of palliative care; and

(B)

the term addiction treatment opioid prescription means a prescription—

(i)

for an opioid drug in schedule II, III, or IV approved by the Food and Drug Administration for an indication for the treatment of addiction; and

(ii)

that is for the treatment of addiction.

(2)

Three-day limit

The Attorney General may not register, or renew the registration of, a practitioner under subsection (f) who is licensed under State law to prescribe controlled substances in schedule II, III, or IV, unless the practitioner submits to the Attorney General, for each such registration or renewal request, a certification that the practitioner, during the applicable registration period, will not prescribe any opioid in schedule II, III, or IV, other than an addiction treatment opioid prescription, for the initial treatment of acute pain in an amount in excess of a 3-day supply.

.

4.

First responder training

Section 546 of the Public Health Service Act (42 U.S.C. 290ee–1) is amended—

(1)

in subsection (c)—

(A)

in paragraph (2), by striking and at the end;

(B)

in paragraph (3), by striking the period and inserting ; and; and

(C)

by adding at the end the following:

(4)

train and provide resources for first responders and members of other key community sectors on safety around fentanyl and other dangerous illicit drugs to protect themselves from exposure and respond appropriately when exposure occurs.

;

(2)

in subsection (d), by inserting , and safety around fentanyl and other dangerous illicit drugs before the period;

(3)

in subsection (f)—

(A)

in paragraph (3), by striking and at the end;

(B)

in paragraph (4), by striking the period and inserting a semicolon; and

(C)

by adding at the end the following:

(5)

the number of first responders and members of other key community sectors trained on safety around fentanyl and other dangerous illicit drugs.

; and

(4)

in subsection (g), by inserting before the period the following: , and $300,000,000 for each of fiscal years 2019 through 2023.

5.

Evidence-based prescription opioid and heroin treatment and intervention demonstrations

Section 514B of the Public Health Service Act (42 U.S.C. 290bb–10) is amended—

(1)

in subsection (d), by inserting , and Indian tribes and tribal organizations (as defined in section 4 of the Indian Self-Determination and Education Assistance Act) before the first period; and

(2)

in subsection (f), by inserting before the period the following: , and $300,000,000 for each of fiscal years 2019 through 2023.

6.

Building communities of recovery

Section 547 of the Public Health Service Act (42 U.S.C. 290ee–2) is amended—

(1)

by striking subsection (c);

(2)

by redesignating subsection (d) as subsection (c);

(3)

in subsection (c) (as so redesignated)—

(A)

in paragraph (1), by striking and at the end;

(B)

in paragraph (2)(C)(iv), by striking the period and inserting ; and; and

(C)

by adding at the and the following:

(3)

may be used as provided for in subsection (d).

;

(4)

by inserting after subsection (c) (as so redesignated), the following:

(d)

Establishment of regional technical assistance centers

(1)

In general

Grants awarded under subsection (b) may be used to provide for the establishment of regional technical assistance centers to provide regional technical assistance for the following:

(A)

Implementation of regionally driven peer delivered addiction recovery support services before, during, after, or in lieu of addiction treatment.

(B)

Establishment of recovery community organizations.

(C)

Establishment of recovery community centers.

(D)

Naloxone training and dissemination.

(2)

Eligible entities

To be eligible to receive a grant under paragraph (1), an entity shall be—

(A)

a national nonprofit entity with a network of local affiliates and partners that are geographically and organizationally diverse; or

(B)

a national nonprofit organization established by individuals in personal and family recovery, serving prevention, treatment, recovery, payor, faith-based, and criminal justice stakeholders in the implementation of local addiction and recovery initiatives.

; and

(5)

in subsection (e), by inserting before the period the following: , and $200,000,000 for each of fiscal years 2019 through 2023.

7.

Medication-assisted treatment for recovery from addiction

(a)

Allowing States To raise patient caps under certain conditions; making nurse practitioner and physician assistant authority permanent

Section 303(g)(2) of the Controlled Substances Act (21 U.S.C. 823(g)(2)) is amended—

(1)

in subparagraph (G)(iii)(II), by striking during the period beginning on the date of enactment of the Comprehensive Addiction and Recovery Act of 2016 and ending on October 1, 2021,; and

(2)

in subparagraph (I)—

(A)

in clause (i), by striking or at the end;

(B)

by redesignating clause (ii) as clause (iii); and

(C)

by inserting after clause (i) the following:

(ii)

permits a qualifying practitioner to dispense drugs in schedule III, IV, or V, or combinations of such drugs, for maintenance or detoxification treatment in accordance with this paragraph to a total number of patients that is more than the total number applicable to the qualifying practitioner under subparagraph (B)(ii)(II), including an unlimited number, if the State—

(I)

enacts a law authorizing such dispensing to that increased total number, or unlimited number, of patients;

(II)

before the increased total number or elimination of a limit goes into effect in the State, directs the applicable State agency or regulatory board to adopt statewide regulations governing the use of medications approved by the Food and Drug Administration for the treatment of opioid dependence or for the prevention of relapse to opioid dependence, consistent with nationally recognized evidence-based guidelines produced by a national or international medical professional association, public health entity, or governmental body with the aim of ensuring the appropriate use of evidence to guide individual diagnostic and therapeutic clinical decisions, including the National Practice Guidelines For the Use of Medications in the Treatment of Addiction Involving Opioid Use issued by the American Society of Addiction Medicine; and

(III)

notifies the Attorney General of the increased total number or elimination of a limit; or

.

(b)

Repeal of requirement To update regulations

Section 303 of the Comprehensive Addiction and Recovery Act of 2016 (Public Law 114–198; 130 Stat. 720) is amended by striking subsection (c).

(c)

Definition of qualifying other practitioner

Section 303(g)(2)(G)(iv) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)(iv)) is amended by striking nurse practitioner or physician assistant each place that term appears and inserting nurse practitioner, clinical nurse specialist, certified registered nurse anesthetist, certified nurse midwife, or physician assistant.

(d)

Requirement To offer two types of medication-Assisted treatment

Any entity, including a prison or jail, that receives Federal funds for a program or activity offering medication-assisted treatment shall offer, or have an affiliation with a provider who can prescribe and discuss with patients the risks of, benefits of, and alternatives to—

(1)

not less than 1 opioid antagonist medication approved by the Food and Drug Administration; and

(2)

not less than 1 opioid agonist (or partial agonist) medication approved by the Food and Drug Administration to treat addiction involving opioids.

8.

National youth recovery initiative

(a)

Definitions

In this section:

(1)

Eligible entity

The term eligible entity means—

(A)

a high school that has been accredited as a substance use recovery high school or that is seeking to establish or expand substance use recovery support services;

(B)

an institution of higher education;

(C)

a recovery program at an institution of higher education;

(D)

a nonprofit organization; or

(E)

a technical assistance center that can help grantees install recovery support service programs aimed at youth and young adults which include recovery coaching, job training, transportation, linkages to community-based services and supports, regularly scheduled alternative peer group activities, life-skills education, and leadership development.

(2)

High school

The term high school has the meaning given the term in section 8101 of the Elementary and Secondary Education Act of 1965 (20 U.S.C. 7801).

(3)

Institution of higher education

The term institution of higher education has the meaning given the term in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001).

(4)

Recovery program

The term recovery program means a program—

(A)

to help youth or young adults who are recovering from substance use disorders to initiate, stabilize, and maintain healthy and productive lives in the community; and

(B)

that includes peer-to-peer support delivered by individuals with lived experience in recovery, and communal activities to build recovery skills and supportive social networks.

(b)

Grants authorized

The Assistant Secretary for Mental Health and Substance Use, in consultation with the Secretary of Education, shall award grants, on a competitive basis, to eligible entities to enable the eligible entities to—

(1)

provide substance use recovery support services to youth and young adults enrolled in high school or an institution of higher education;

(2)

help build communities of support for youth and young adults in substance use recovery through a spectrum of activities such as counseling, job training, recovery coaching, alternative peer groups, life-skills workshops, family support groups, and healthy and wellness-oriented social activities; and

(3)

encourage initiatives designed to help youth and young adults achieve and sustain recovery from substance use disorders.

(c)

Application

An eligible entity desiring a grant under this section shall submit to the Assistant Secretary for Mental Health and Substance Use an application at such time, in such manner, and containing such information as the Assistant Secretary may require.

(d)

Use of funds

Grants awarded under subsection (b) may be used for activities to develop, support, or maintain substance use recovery support services for youth or young adults, including—

(1)

the development and maintenance of a dedicated physical space for recovery programs;

(2)

hiring dedicated staff for the provision of recovery programs;

(3)

providing health and wellness-oriented social activities and community engagement;

(4)

the establishment of a substance use recovery high school;

(5)

the coordination of a peer delivered substance use recovery program with—

(A)

substance use disorder treatment programs and systems;

(B)

providers of mental health services;

(C)

primary care providers;

(D)

the criminal justice system, including the juvenile justice system;

(E)

employers;

(F)

recovery housing services;

(G)

child welfare services;

(H)

high schools; and

(I)

institutions of higher education;

(6)

the development of peer-to-peer support programs or services delivered by individuals with lived experience in addiction recovery; and

(7)

any additional activity that helps youth or young adults achieve recovery from substance use disorders.

(e)

Resource center

The Assistant Secretary for Mental Health and Substance Use shall establish a resource center to provide technical support to recipients of grants under this section.

(f)

Authorization of appropriations

There are authorized to be appropriated to carry out this section $10,000,000 for fiscal year 2019 and each of the 4 succeeding fiscal years.

9.

National recovery residence standards

(a)

Best practices for operating recovery housing

The Secretary of Health and Human Services, acting through the Director of the Center for Substance Abuse Treatment of the Substance Abuse and Mental Health Services Administration—

(1)

shall publish best practices for operating recovery housing, based on—

(A)

the applicable domains, core principles, and standards of the National Alliance for Recovery Residences; and

(B)

input from other nationally accredited recovery housing entities and from stakeholders;

(2)

shall disseminate such best practices to each State;

(3)

may provide technical assistance to States seeking to adopt or implement such best practices;

(4)

shall identify barriers with respect to recovery housing, State licensure, zoning restrictions, and discrimination against individuals receiving medication assisted treatment for the treatment of opioid abuse; and

(5)

shall develop strategies to address the barriers identified under paragraph (4).

(b)

Definitions

In this section:

(1)

The term recovery housing means a family-like, shared living environment free from alcohol and illicit drug use and centered on peer support and connection to services that promote sustained recovery from substance use disorders.

(2)

The term State includes any of the several States, the District of Columbia, and any territory or possession of the United States.

10.

Improving treatment for pregnant and postpartum women

Section 508(s) of the Public Health Service Act (42 U.S.C. 290bb–1(s)) is amended in the first sentence by inserting before the period the following: , and $100,000,000 for each of fiscal years 2019 through 2023.

11.

Veterans treatment courts

Section 2991(o)(3) of title I of the Omnibus Crime Control and Safe Streets Act of 1968 (34 U.S.C. 10651(o)(3)) is amended—

(1)

by striking Limitation and inserting Veterans;

(2)

by striking Not more than and inserting the following:

(A)

Limitation

Not more than

;

(3)

in subparagraph (A), as so designated, by striking this section and inserting paragraph (1); and

(4)

by adding at the end the following:

(B)

Additional funding

In addition to the amounts authorized under paragraph (1), there are authorized to be appropriated to the Department of Justice to carry out subsection (i) $20,000,000 for each of fiscal years 2019 through 2023.

.

12.

Infant plan of safe care

Section 112 of the Child Abuse Prevention and Treatment Act (42 U.S.C. 5106h) is amended by adding at the end the following:

(c)

Infant plan of safe care

In addition to amounts otherwise appropriated to carry out this title, there is authorized to be appropriated $60,000,000 for each of fiscal years 2019 through 2023, to provide funds for States to collaboratively develop policies and procedures concerning implementing and developing systems to monitor plans of safe care under section 106(b)(2)(B)(iii).

.

13.

Require the use of prescription drug monitoring programs

(a)

Definitions

In this section:

(1)

Controlled substance

The term controlled substance has the meaning given the term in section 102 of the Controlled Substances Act (21 U.S.C. 802).

(2)

Covered State

The term covered State means a State that receives funding under the Harold Rogers Prescription Drug Monitoring Program established under the Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations Act, 2002 (Public Law 107–77; 115 Stat. 748), under this Act (or an amendment made by this Act), or under the controlled substance monitoring program under section 399O of the Public Health Service Act (42 U.S.C. 280g–3).

(3)

Dispenser

The term dispenser

(A)

means a person licensed or otherwise authorized by a State to deliver a prescription drug product to a patient or an agent of the patient; and

(B)

does not include a person involved in oversight or payment for prescription drugs.

(4)

PDMP

The term PDMP means a prescription drug monitoring program.

(5)

Practitioner

The term practitioner means a practitioner registered under section 303(f) of the Controlled Substances Act (21 U.S.C. 823(f)) to prescribe, administer, or dispense controlled substances.

(6)

State

The term State means each of the several States and the District of Columbia.

(b)

In general

Beginning 1 year after the date of enactment of this Act, each covered State shall require—

(1)

each prescribing practitioner within the covered State or their designee, who shall be licensed or registered healthcare professionals or other employees who report directly to the practitioner, to consult the PDMP of the covered State before initiating treatment with a prescription for a controlled substance listed in schedule II, III, or IV of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)), and every 3 months thereafter as long as the treatment continues;

(2)

the PDMP of the covered State to provide proactive notification to a practitioner when patterns indicative of controlled substance misuse, including opioid misuse, are detected;

(3)

each dispenser within the covered State to report each prescription for a controlled substance dispensed by the dispenser to the PDMP not later than 24 hours after the controlled substance is dispensed to the patient;

(4)

that the PDMP make available a quarterly de-identified data set and an annual report for public and private use, including use by healthcare providers, health plans and health benefits administrators, State agencies, and researchers, which shall, at a minimum, meet requirements established by the Attorney General, in coordination with the Secretary of Health and Human Services;

(5)

each State agency that administers the PDMP to—

(A)

proactively analyze data available through the PDMP; and

(B)

provide reports to law enforcement agencies and prescriber licensing boards describing any prescribing practitioner that repeatedly fall outside of expected norms or standard practices for the prescribing practitioner’s field; and

(6)

that the data contained in the PDMP of the covered State be made available to other States.

(c)

Noncompliance

If a covered State fails to comply with subsection (a), the Attorney General or the Secretary of Health and Human Services may withhold grant funds from being awarded to the covered State under the Harold Rogers Prescription Drug Monitoring Program established under the Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations Act, 2002 (Public Law 107–77; 115 Stat. 748), under this Act (or an amendment made by this Act), or under the controlled substance monitoring program under section 399O of the Public Health Service Act (42 U.S.C. 280g–3).

14.

Increasing civil and criminal penalties for opioid manufacturers

Section 402(c) of the Controlled Substances Act (21 U.S.C. 842(c)) is amended—

(1)

in paragraph (1)(B), by striking shall not exceed $10,000. and inserting the following: “shall not exceed—

(i)

except as provided in clause (ii), $10,000; and

(ii)

if the violation is committed by a manufacturer of opioids and relates to the reporting of suspicious orders for opioids or failing to maintain effective controls against diversion of opioids, $100,000.

; and

(2)

in paragraph (2)—

(A)

in subparagraph (A), by inserting or (D) after subparagraph (B); and

(B)

by adding at the end the following:

(D)

In the case of a violation referred to in subparagraph (A) that was a violation of paragraph (5) or (10) of subsection (a) committed by a manufacturer of opioids that relates to the reporting of suspicious orders for opioids or failing to maintain effective controls against diversion of opioids, the criminal fine under title 18, United States Code, shall not exceed $500,000.

.